122 related articles for article (PubMed ID: 25721008)
1. The Optimal Treatment Modality in Patients with T4N2M0 Non-Small Cell Lung Cancer: The Best Choice May Be Definitive Chemoradiotherapy Followed by Consolidation Chemotherapy.
Mutlu H; Arslan D; Gündüz Ş; Tural D; Büyükçelik A; Benderli Cihan Y; Aslan T; Bozcuk H; Şenol Coşkun H
Chemotherapy; 2014; 60(2):107-111. PubMed ID: 25721008
[TBL] [Abstract][Full Text] [Related]
2. GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer.
Flentje M; Huber RM; Engel-Riedel W; Andreas S; Kollmeier J; Staar S; Dickgreber N; Vaissiere N; De Almeida C; Edlich B; Fietkau R
Strahlenther Onkol; 2016 Apr; 192(4):216-22. PubMed ID: 26809652
[TBL] [Abstract][Full Text] [Related]
3. Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01.
Fournel P; Vergnenégre A; Robinet G; Léna H; Gervais R; Le Caer H; Souquet PJ; Chavaillon JM; Bozonnat MC; Daurès JP; Chouaid C; Martel-Lafay I;
Eur J Cancer; 2016 Jan; 52():181-7. PubMed ID: 26689864
[TBL] [Abstract][Full Text] [Related]
4. [Concurrent chemoradiotherapy followed by consolidation chemotherapy and sequential chemoradiotherapy for stage III non-small cell lung cancer: comparison in 93 patients].
Sun WZ; Song LP; Zhang YB; Ai T; Lu JL; Ren J; Gao Y
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Mar; 32(3):362-7. PubMed ID: 22445984
[TBL] [Abstract][Full Text] [Related]
5. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
[TBL] [Abstract][Full Text] [Related]
6. Concurrent chemoradiotherapy followed by consolidation chemotherapy with bi-weekly docetaxel and carboplatin for stage III unresectable, non-small-cell lung cancer: clinical application of a protocol used in a previous phase II study.
Saitoh J; Saito Y; Kazumoto T; Kudo S; Yoshida D; Ichikawa A; Sakai H; Kurimoto F; Kato S; Shibuya K
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1791-6. PubMed ID: 21601375
[TBL] [Abstract][Full Text] [Related]
7. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
8. Locally advanced non-small cell lung cancer: what is the optimal concurrent chemoradiation regimen?
Videtic GM
Cleve Clin J Med; 2012 May; 79 Electronic Suppl 1():eS32-7. PubMed ID: 22614963
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of celecoxib with docetaxel chemoradiotherapy followed by consolidation chemotherapy docetaxel plus cisplatin with maintenance celecoxib in inoperable stage III nonsmall cell lung cancer.
Takhar H; Singhal N; Mislang A; Kumar R; Kim L; Selva-Nayagam S; Pittman K; Karapetis C; Borg M; Olver IN; Brown MP
Asia Pac J Clin Oncol; 2018 Feb; 14(1):91-100. PubMed ID: 28840978
[TBL] [Abstract][Full Text] [Related]
10. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
[TBL] [Abstract][Full Text] [Related]
11. Phase II study. Concurrent chemotherapy and radiotherapy with nitroglycerin in locally advanced non-small cell lung cancer.
Arrieta O; Blake M; de la Mata-Moya MD; Corona F; Turcott J; Orta D; Alexander-Alatorre J; Gallardo-Rincón D
Radiother Oncol; 2014 May; 111(2):311-5. PubMed ID: 24836861
[TBL] [Abstract][Full Text] [Related]
12. Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival.
Gielda BT; Mehta P; Khan A; Marsh JC; Zusag TW; Warren WH; Fidler MJ; Abrams RA; Bonomi P; Liptay M; Faber LP
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):985-91. PubMed ID: 20932684
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
[TBL] [Abstract][Full Text] [Related]
14. Impact of prophylactic cranial irradiation timing on brain relapse rates in patients with stage IIIB non-small-cell lung carcinoma treated with two different chemoradiotherapy regimens.
Topkan E; Parlak C; Kotek A; Yuksel O; Cengiz M; Ozsahin M; Pehlivan B
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1264-71. PubMed ID: 22172902
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of BIM deletion polymorphism in chemoradiotherapy for non-small cell lung cancer.
Wakabayashi Y; Masuda T; Fujitaka K; Nakashima T; Okumoto J; Shimoji K; Nishimura Y; Yamaguchi K; Sakamoto S; Horimasu Y; Miyamoto S; Iwamoto H; Ohshimo S; Hamada H; Hattori N
Cancer Sci; 2021 Jan; 112(1):369-379. PubMed ID: 33103296
[TBL] [Abstract][Full Text] [Related]
16. Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer.
Tanaka F; Yokomise H; Soejima T; Uramoto H; Yamanaka T; Nakagawa K; Yamamoto N; Nishimura Y; Niwa H; Okada M; Nakagawa T; Yamashita M
Ann Thorac Surg; 2018 Oct; 106(4):1018-1024. PubMed ID: 29890150
[TBL] [Abstract][Full Text] [Related]
17. Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy--retrospective analysis of 203 cases.
Liu L; Bi N; Ji Z; Li J; Wang J; Wang X; Hui Z; Lv J; Liang J; Zhou Z; Wang Y; Yin W; Wang L
BMC Cancer; 2015 Oct; 15():715. PubMed ID: 26474893
[TBL] [Abstract][Full Text] [Related]
18. Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy.
Palomar-Abril V; Soria-Comes T; Campos ST; Ureste MM; Bosch VG; Maiques ICM
Clin Transl Oncol; 2020 Dec; 22(12):2333-2340. PubMed ID: 32449125
[TBL] [Abstract][Full Text] [Related]
19. Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience.
Mertsoylu H; Köse F; Sümbül AT; Sedef AM; Doğan Ö; Besen AA; Parlak C; Fındıkçıoğlu A; Muallaoğlu S; Sezer A; Sakallı H; Özyılkan Ö
Med Sci Monit; 2015 Mar; 21():661-6. PubMed ID: 25731741
[TBL] [Abstract][Full Text] [Related]
20. Weekly docetaxel and cisplatin with concomitant radiotherapy in addition to surgery and/or consolidation chemotherapy in stage III non-small cell lung cancer.
Sen F; Saglam EK; Toker A; Dilege S; Kizir A; Oral EN; Saip P; Sakallioglu B; Topuz E; Aydiner A
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1497-505. PubMed ID: 21499895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
